New trial
Phase III Olaparib PARP Inhibitor Maintenance in Ovarian Cancer
- Trial ID
- NCT06580314 on ClinicalTrials.gov
- Cancer type
- Ovarian Cancer
- Stage of research
- Registrational
- Location
- 342 Locations
- Published in
- New in Oncology - July 3, 2025
This phase III trial compares one versus two years of maintenance olaparib—with or without bevacizumab—in patients with BRCA1/2-mutated or HRD+ stage III-IV ovarian cancer following first-line platinum-based chemotherapy. NRG Oncology is evaluating the optimal olaparib duration to delay disease progression.
More in ovarian cancer
-
Trial result · Oct 22, 2026 · NCT07213804
Sofetabart mipitecan (FRα-targeted ADC) posts 50.5% ORR and 8.1-mo mPFS in heavily pretreated HGOC—without keratopathy -
New trial · Oct 15, 2026 · NCT07851025
Phase 3 TREVI-OC-02 tests FRα-targeted torvutatug samrotecan plus bevacizumab maintenance in HRD-negative ovarian cancer -
New trial · Oct 15, 2026 · NCT07504588
Phase 2 NRG-GY038 compares sacituzumab govitecan plus bevacizumab with platinum-based treatment after PARP-inhibitor progression -
New trial · Oct 15, 2026 · NCT07776691
Phase 3 REJOICE-Ovarian04 tests CDH6-targeted raludotatug deruxtecan maintenance with or without bevacizumab -
New trial · Oct 8, 2026 · NCT07816666
Phase 3 torvutatug samrotecan FRα (FOLR1) ADC with exatecan (topoisomerase I) payload